Financial Times FT.com

FDA advisory panel today with Bayer, GE Healthcare on imaging biomarkers in Alzheimer's will affect disease modification drug trials

By Kimberly Ha and Elizabeth Krutoholow in New York

Published: October 23 2008 18:59 | Last updated: October 23 2008 18:59

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)